RubrYc Therapeutics, Inc., is a biotechnology company applying proprietary machine-learning and computational biology solutions to discover epitope-selective biotherapeutics. Inspired by recent advances in molecular library synthesis, massively parallel screening and computing, RubrYc is forging a new path for information-driven discovery of therapeutic antibodies.
Founded in 2017, RubrYc Therapeutics, Inc. emerged as the exclusive biotherapeutic partner of immunomics leader HealthTell. In April 2018, RubrYc Therapeutics, Inc. spun out of HealthTell, and has leveraged the RubrYc Discovery Engine technology to advance proprietary discovery programs, and to partner with top-tier pharmaceutical companies that share our mission to expand therapeutic options and improve outcomes with novel, epitope-targeted biotherapeutics. RubrYc is backed by a strong syndicate of investors, including Third Point Ventures, Paladin Capital Group, and Vital Venture Capital. The company is based in San Carlos, California.
RubrYc Therapeutics is a trusted drug discovery partner, and thrives on opportunities to discover and drive new medicines for unmet medical needs.
We Promise Accountability
From data quality to on-time reporting, we follow through on our commitments. We are passionate about the impact of our technology, guiding discovery of new therapies for our partners and patients in need.
We Value Reliability
We practice science with rigor and consistency. We provide our partners dependable, actionable results.
We Offer Flexibility
We provide multiple antibody discovery services for partner-supplied mAbs, including: functional epitope mapping, immunization strategy and immunogen design, and on- and off-target binding prediction.
We Create Value
When a partner specifies drug targets to launch discovery campaigns, we efficiently deploy resources throughout the discovery process to deliver de-risked and demonstratively efficacious drug candidates.